Oral contraceptives, lanosterol, and platelet hyperactivity in rat

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Platelets play a crucial role in hemostasis and thrombosis.
• Oral contraceptives can influence platelet function and increase thrombotic risk.
• Lanosterol, a cholesterol precursor, is elevated in platelets of rats using oral contraceptives.

Purpose of the Study:

• To investigate the effect of lanosterol on platelet activity.
• To determine if lanosterol or its related compounds (cholesterol, ethinylestradiol) are responsible for increased platelet activity observed with oral contraceptives.

Main Methods:

• Incubation of lanosterol with rat platelet-rich plasma and washed platelet suspensions.
• Measurement of platelet activity via clotting time and platelet aggregation assays.
• Comparative incubation with cholesterol and ethinylestradiol.

Main Results:

• Lanosterol induced a dose-related increase in platelet activity within 2 minutes.
• This hyperactivity was evident in both clotting time and platelet aggregation.
• Cholesterol and ethinylestradiol did not reproduce the observed platelet hyperactivity.

Conclusions:

• Lanosterol, not cholesterol or ethinylestradiol, is the likely agent responsible for the increased platelet activity associated with oral contraceptives.
• Lanosterol directly enhances platelet function, suggesting a potential mechanism for oral contraceptive-induced thrombotic events.